TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04525014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RRx-001
Description: RRx-001 will be administered every 3 weeks via intravenous infusion at three dose levels: 0.5 mg/m2 (Max 1 mg), 1 mg/m2 (Max 2 mg), and 2 mg/m2 (Max 4 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100 mg/m2 (children ≥0.5 m2) or 3 mg/kg (children \<0.5 m2) daily for 5 days beginning on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 90 mg/m2 taken orally daily for 5 days administered 1 hour after temozolomide
Study: NCT06539507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX17725
Description: BCX17725 for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for injection
Study: NCT05741905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin is a quinolone antibiotics and newly identified neuro-protective agent. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levofloxacin simulant
Description: Levofloxacin simulant is placebo. Intravenous thrombolysis is one of the treatments for acute ischemic stroke.
Study: NCT05813067

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: JDS-HF 3.0
Description: Take 2 capsules once daily in the mornings with food

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 2 capsules once daily in the mornings with food
Study: NCT04930237

Intervention type: DRUG
Intervention: Relistor Injectable Product
Description: 12-mg RELISTOR to be administered as once-daily subcutaneous injections for 4 to 7 days

Intervention type: DRUG
Intervention: Docusate Calcium
Description: Standard of care

Intervention type: DRUG
Intervention: Bisacodyl
Description: Standard of Care

Intervention type: DRUG
Intervention: Milk of magnesia
Description: Standard of Care

Intervention type: DRUG
Intervention: Magnesium citrate
Description: Standard of Care

Intervention type: DRUG
Intervention: Senna
Description: Standard of Care

Intervention type: DRUG
Intervention: Enema
Description: Standard of Care
Study: NCT06267976

Intervention type: DEVICE
Intervention: ProSomnus RPMO2
Description: The ProSomnus RPMO2 device is an intraoral reflectance pulse oximeter.
Study: NCT05188755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetric test during submaximal exercise
Description: * metabolic evaluation by indirect calorimetry at rest and during exercise~* evaluation of cardiac output~* peripheral quantitative computed tomography (pQCT) of the muscle cross section~* evaluation of body composition~* assessment of physical capacity (chair test and 3 min step-test)~* blood test~* assess the level of physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect calorimetric test during submaximal exercise
Description: * metabolic evaluation by indirect calorimetry at rest and during exercise~* evaluation of cardiac output~* peripheral quantitative computed tomography (pQCT) of the muscle cross section~* evaluation of body composition~* assessment of physical capacity (chair test and 3 min step-test)~* blood test~* assess the level of physical activity
Study: NCT04549311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic 1 arm (amoxicillin + clavulanic acid)
Description: Prescription of antibiotics (amoxicillin + clavulanic acid) after incision and drainage of perianal abscess.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic 2 arm (ciprofloxacin + metronidazole)
Description: Prescription of antibiotics (ciprofloxacin + metronidazole) after incision and drainage of perianal abscess.
Study: NCT04591977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV Self-Sampling Kit (Evalyn Brush)
Description: The Evalyn Brush is a self-sampling kit that can be used to collect a sample to screen for HPV/Cervical cancer at home.
Study: NCT06624904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 50mg
Description: Single dose losartan (50 mg), encapsulated identically to placebo.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single tablet encapsulated identically to placebo.
Study: NCT06325137

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptome analyses
Description: A sample of peripheral whole blood cells will be collected at the onset before the initiation of steroid treatment (time 0, t0) and after 6 weeks at the definition of steroid sensitivity/unresponsiveness (time 1, t1).

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcriptome analyses
Description: A sample of peripheral whole blood cells will be collected at the onset before the initiation of steroid treatment (time 0, t0) and after 6 weeks at the definition of steroid sensitivity/unresponsiveness (time 1, t1).
Study: NCT06178783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Brensocatib oral solutions will be expectorated following the tasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Brensocatib oral solutions will be expectorated following the tasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Brensocatib oral solutions will be expectorated following the tasting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Brensocatib oral solutions will be expectorated following the tasting.
Study: NCT05225298

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Offering SARS-CoV-2 test
Description: A pragmatic cluster (facility-level) randomized clinical trial, comparing test-based screening performed at a static (every two weeks) frequency versus a dynamic frequency (ranging from once a week to once every four weeks) anchored to county COVID-19 case rates

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Offering SARS-CoV-2 test
Description: A pragmatic cluster (facility-level) randomized clinical trial, comparing test-based screening performed at a static (every two weeks) frequency versus a dynamic frequency (ranging from once a week to once every four weeks) anchored to county COVID-19 case rates
Study: NCT04717050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive combine training (PCT)
Description: 8 month exercise program with 4 month follow up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control (AC)
Description: 12 month stretching program
Study: NCT03484936

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.
Study: NCT05046379

Intervention type: OTHER
Intervention: Lipidomics
Description: Lipidomics is the large-scale study of lipids (fats and fat-like molecules) within biological systems. It involves identifying and quantifying the wide variety of lipids in cells, tissues, or organisms to understand their roles in metabolism, signaling, and disease. Lipidomics is a subfield of metabolomics and uses advanced analytical techniques, like mass spectrometry, to profile lipid molecules. It helps in studying how lipids contribute to cellular functions, disease development, and responses to therapies.

Intervention type: OTHER
Intervention: Lipidomics
Description: Lipidomics is the large-scale study of lipids (fats and fat-like molecules) within biological systems. It involves identifying and quantifying the wide variety of lipids in cells, tissues, or organisms to understand their roles in metabolism, signaling, and disease. Lipidomics is a subfield of metabolomics and uses advanced analytical techniques, like mass spectrometry, to profile lipid molecules. It helps in studying how lipids contribute to cellular functions, disease development, and responses to therapies.
Study: NCT06163742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Product X
Description: The investigational device is a polyethylene glycol-based biomaterial. It can be applied to donor sites on the arms, torso, and legs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care
Description: The active comparator includes the current standard-of-care treatment: hydrocellular polyurethane dressing covered with TegadermTM film for 48 hours, followed by an occlusive gauze impregnated with 3% Bismuth Tribromorphenate in petrolatum.
Study: NCT05180721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of patient portal for diabetes management
Description: A multi-level intervention aimed at increasing access and use of patient portals for diabetes management (MAP) in community health centers (CHCs).
Study: NCT06089408

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Use a regular blanket

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Use a weighted blanket
Study: NCT05040022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pneumoperitoneum pressure 10 mmHg
Description: The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 10 mmHg (group 10)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pneumoperitoneum pressure 14 mmHg
Description: The abdomen will be inflated with carbon dioxide to maintain the intra-abdominal pressure at 14 mmHg (group 14).
Study: NCT05065190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Description: nintedanib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05763953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etripamil NS
Description: Part 1A: At least 12 patients will be administered with Etripamil NS (35 mg/100 μL per nostril) at a dose of 70 mg.~Part 1B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 1A.~Part 2A: At least 12 patients will be administered with Etripamil NS at a dose selected based on appropriate body size-based modeling using PK assessments, as well as safety/tolerability, and efficacy data collected in Part 1.~Part 2B: At least 18 following patients will be administered with Etripamil NS at a dose determined by analysis of data generated from Part 2A.
Study: NCT05918562

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low fiber diet
Description: Low fiber diet including cereal, white bread, eggs, meat, dairy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard clear liquid diet
Description: Standard clear liquid diet including broth, jello, water, juice
Study: NCT06089408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05762614

Intervention type: OTHER
Intervention: Dyspnea assessment
Description: Dyspnea assessment, respiratory variability, Spirometry, Electromyography
Study: NCT05624866

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: injection of 1 microgram/kg dexmeditomidine + 10 cc saline injection nearby median nerve as hydro-dissection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: injection of 40 mg triamcinolone + 10 cc saline injection nearby median nerve as hydro-dissection
Study: NCT05434143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chorus Sleep
Description: During the 6-week intervention, participants will receive daily reminders to complete their daily sleep log and a link to a chorus sleep class for them to listen to that night.~The daily sleep class involve listening to 15 minute audio sessions, which include guided mediation and breathing exercises.
Study: NCT05496972

Intervention type: BEHAVIORAL
Intervention: Survey Administration
Description: Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine
Study: NCT04719403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealthPAL
Description: Participants who are randomly assigned to the HealthPAL arm will have immediate post- visit access to audio/video-recordings of their clinical visit through a HIPAA-compliant web-based program called HealthPAL.
Study: NCT06307119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy and Relaxation Group
Description: MOHO Based Intervention~The client-centered occupational therapy comprises five distinct stages:~1. Client-Centered Goal Setting:It involves collaboratively establishing goals the client's needs and aspirations.~2. Creating the Therapy Plan:Comprehensive therapy plan is devised from the findings from OSA and MOHOST results.~3. Implementing the Interventions:These interventions aimed addressing various personal challenges,financial management,stress management.~4. Evaluating the Results:It involves adjusting the therapy plan as needed based on the participant's responses and outcomes.~5. Receiving Feedback~Jacobson's Progressive Muscle Relaxation~Starting with the lower extremities,participants sequentially tensed and relaxed muscle groups,moving from distal to proximal regions,encompassing toes,ankles,thighs,buttocks,abdomen,fingers,triceps,shoulders,and face.During all these stages,it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Group
Description: Jacobson's Progressive Muscle Relaxation (JPMR) Participants underwent training in relaxation techniques involving mental visualization and Jacobson's progressive muscle relaxation method with the aid of music. Starting with the lower extremities, participants sequentially tensed and relaxed muscle groups, moving from distal to proximal regions, encompassing toes, ankles, thighs, buttocks, abdomen, fingers, triceps, shoulders, cervical muscles, and face. During all these stages, it was ensured to maintain contraction for 5 seconds and to relax and rest for 10 seconds.
Study: NCT04988425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNFα Monoclonal Antibody
Description: Subcutaneous injection of 50mg of TNFα monoclonal antibody immediately after admission before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Injection of 500mg of methylprednisolone immediately after admission before surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection of the same volume of saline immediately after admission before surgery
Study: NCT05765084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination
Description: WT1/DC vaccines (8-10 x 10\^6 cells in 500 μL saline solution with 5% human albumin) will be administered through intradermal injection at 5 sites (100 μL/site) in the ventromedial region of the upper arm (5-10 cm from the axillary lymph nodes). Injection sites will alternate between left and right arms. WT1/DC vaccines are administered on day 14 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Additional WT1/DC vaccinations after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab (1200 mg) will be administered on day 0 of each 3-weekly platinum/pemetrexed-based chemotherapy cycle. Atezolizumab should be administered before chemotherapy administration as an IV infusion over 60 (±15) minutes. If the first infusion is tolerated, all subsequent infusions may bedelivered over 30 (±10) minutes. Additional atezolizumab treatment (1680 mg) after the study treatment schedule can be administered (optional) at 4-weekly intervals (± 1 week) as an IV infusion over 30-60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum/pemetrexed based chemotherapy
Description: On the first day of each cycle (day 0), pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes, followed by cisplatin 75 mg/m2 as IV over approximately 2 hours. The actual doses of the drugs to be administered to patients will be determined by calculating the patient's body surface area at the beginning of each cycle. For ease of dose administration, the protocol allows ± 5% variance in the calculated total dose per infusion. If deemed necessary, the treating physician can decide to replace cisplatin by carboplatin. In that case, carboplatin will be delivered to an area under the concentration-time curve (AUC) of 5 as an IV infusion over 1 hour.
Study: NCT06158763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT guided self-help Interventions
Description: An existing CBT-based transdiagnostic self-help manual (Naeem et al., 2014) that has been used successfully in RCTs (Amin et al., 2020; Naeem et al., 2014) and has been used as an online intervention (http://khushiorkhatoon.com/) will be further adapted. The intervention consists of seven modules, including cognitive restructuring, problem-solving and behavioural activation.
Study: NCT06326255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter yoga
Description: each class, including warm-up exercises, laughter yoga exercises, breathing and a relaxation session and sharing
Study: NCT05600725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: novel atrial pacing approach
Description: See US Patent #10987516. An atrial pacing method that preserves atrioventricular and interventricular synchrony to reproduce an exercise-typical envelope of heart rate.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham pacing approach
Description: A pacemaker/ICD interrogator/programmer will be used to simulate changes in pacing rate over the same time period as the intervention group but the programming changes will not actually be implemented and not change in paced heart rate will occur.
Study: NCT05975502

Intervention type: OTHER
Intervention: Epidemiological study
Description: Study of epidemiological characteristics of women with syphilis during pregnancy and of children born from mothers with syphilis during pregnancy.

Intervention type: OTHER
Intervention: Epidemiological study
Description: Study of epidemiological characteristics of women with syphilis during pregnancy and of children born from mothers with syphilis during pregnancy.
Study: NCT05773209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RLRL device
Description: Crossover device (RLRL of 5% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RLRL device
Description: Crossover device (RLRL of 5% or 100% intensity - alternate to first group). Cross over arms after one month of use and one month of washout period.
Study: NCT04848116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an investigational drug in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is an investigational drug in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuMax-IL8
Description: HuMax-IL8 is an investigational drug in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuMax-IL8
Description: HuMax-IL8 is an investigational drug in this study.
Study: NCT05335668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Testing
Description: Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Testing
Description: Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Testing
Description: Clinical testing for neurological deficits based on National Institute of Health Stroke Scale (NIHSS), objective sensory testing and pain assessment by quantitative sensory testing (QST) and quantitative pain drawings, 7T magnetic resonance imaging (MRI)
Study: NCT06632340

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TUR-BT
Description: Transurethral resection of bladder tumor

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TUR-BT
Description: Transurethral resection of bladder tumor
Study: NCT05254834

Intervention type: DIAGNOSTIC_TEST
Intervention: Freenome Test
Description: Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.

Intervention type: DIAGNOSTIC_TEST
Intervention: Freenome Test
Description: Participants who provide informed consent, meet the eligibility criteria and provide a blood sample for this study will be enrolled.
Study: NCT06008288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-21822
Description: 800mg, orally QD with 21 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
Study: NCT05188729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTX-315 Part 1
Description: LTX-315 once-daily dosing; starting total daily dose of 2 mg for the first subject. Ascending once-daily 1 mg dosing increments (eg, 2 mg on Day 1, 3 mg on Day 2). Subjects may be treated for a maximum of 2 weeks and a maximum total daily dose of 8 mg in Part 1. The starting dose will be escalated between subject cohorts in 1-mg increments after the previous cohort has completed Week 1 dosing (the DLT observation period).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-315 Part 2
Description: VP-315 once-daily dosing; Part 2 will be initiated upon completion of Part 1 to determine the optimal dosing regimen of VP-315. There were no DLTs observed in Part 1 of the study and the maximum dose of 8 mg was achieved. Therefore, the dose to be evaluated in Part 2 will be a total daily dose of 8 mg in 4 Cohorts.
Study: NCT05347121

Intervention type: DIAGNOSTIC_TEST
Intervention: difficult airway
Description: ultrasonography of airway